A Phase 2a Open-label Study to Investigate Safety and Tolerability (Including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination With Lenalidomide in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2019
At a glance
- Drugs Lenalidomide (Primary) ; MT 3724 (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Molecular Templates
- 08 Feb 2019 Planned initiation date changed from 3 Dec 2018 to 1 Mar 2019.
- 13 Nov 2018 According to a Molecular Templates media release, the company expects to start this second phase II combination study with MT-3724 and Revlimid (lenalidomide) in earlier lines of DLBCL in 1Q19.
- 30 Aug 2018 New trial record